CardioVascular BioTherapeutics Inc (CVBT.OB) Puts New Technology to the Test to Halt Heart Disease
Shares of CardioVascular BioTherapeutics Inc. (OTCBB: CVBT) rose 16.3 percent Friday to $1.07 due to highlights of its new angiogenesis treatment for those suffering from heart disease.Cardiovascular disease is no doubt a big issue for not only those inflicted with it, but also for a highly scrutinized healthcare system, due to the cost of necessary treatments. This disease strikes over 36 percent of the population in the U.S., resulting in 2,400 deaths each day. With this in mind, people in the medical industry have been waiting a long time for a better approach to angiogenesis treatment, which is the growth…